Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype-Reference-Cited by-同舟云学术

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype

Published:2015-03-08 Issue:1 Volume:12 Page:
ISSN:1742-2094
Container-title:Journal of Neuroinflammation
language:en
Short-container-title:J Neuroinflammation

Author:

Pröbstel Anne-Katrin,Rudolf Gabrielle,Dornmair Klaus,Collongues Nicolas,Chanson Jean-Baptiste,Sanderson Nicholas SR,Lindberg Raija LP,Kappos Ludwig,de Seze Jérôme,Derfuss Tobias

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Neurology,Immunology,General Neuroscience

Link

http://link.springer.com/content/pdf/10.1186/s12974-015-0256-1.pdf

Reference27 articles.

1. de Seze J, Stojkovic T, Ferriby D, Gauvrit J-Y, Montagne C, Mounier-Vehier F, et al. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J Neurol Sci. 2002;197:57–61.

2. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66:1485–9.

3. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–15.

4. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364:2106–12.

5. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630–43.

Cited by 148 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11

2. Challenges in the interpretation of positive MOG antibody testing in daily MS practice;Multiple Sclerosis and Related Disorders;2024-09

3. Therapeutic Management of Transverse Myelitis Secondary to Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease;American Journal of Therapeutics;2024-07

4. Prevalence of anti-myelin oligodendrocyte glycoprotein antibodies across neuroinflammatory and neurodegenerative diseases;Journal of the Neurological Sciences;2024-06

5. The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease;Journal of Neurology, Neurosurgery & Psychiatry;2024-01-30